Department of Pharmacology and Neuroscience, and the Institute for Healthy Aging , University of North Texas Health Science Center , 3500 Camp Bowie Boulevard , Fort Worth , Texas 76107-2699 , United States.
ACS Chem Neurosci. 2018 Nov 21;9(11):2528-2533. doi: 10.1021/acschemneuro.8b00184. Epub 2018 Jun 5.
Uterotrophic effect of 17α-estradiol, the C17 epimer of the main human estrogen 17β-estradiol, was shown to manifest in animal models at doses lower than those necessary for central outcome raising concerns about its potential to treat maladies of the central nervous system. We introduce here 10β,17α-dihydroxyestra-1,4-dien-3-one (α-DHED) that acts as a bioprecursor prodrug producing 17α-estradiol with remarkable selectivity to the brain and, therefore, without appreciable exposure of the periphery to the parent steroid. This distinguishing feature of α-DHED is shown by using an estrogen-responsive mouse model with complementary LC-MS/MS measurement of drug contents in target tissues. Our data warrant further research to fully establish the potential of α-DHED for a safe and efficacious 17α-estradiol-based neurotherapy.
17α-雌二醇(17β-雌二醇的 C17 差向异构体)具有子宫营养作用,其在动物模型中的作用剂量低于升高中枢神经系统疾病治疗效果所需的剂量,这引起了人们的关注。我们在这里引入 10β,17α-二羟基雌-1,4-二烯-3-酮(α-DHED),它作为一种生物前体前药,可产生具有显著脑选择性的 17α-雌二醇,因此,母体类固醇对外周组织的暴露可以忽略不计。使用雌激素反应性小鼠模型和对靶组织中药物含量进行互补的 LC-MS/MS 测量,可证明 α-DHED 具有这种独特的特征。我们的数据证明了进一步研究 α-DHED 用于安全有效的基于 17α-雌二醇的神经治疗的潜力。